Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal

Fabio Marsico, Milena Cecere, Antonio Parente, Stefania Paolillo, Fabiana de Martino, Santo Dellegrottaglie, Bruno Trimarco, Pasquale Perrone Filardi

Research output: Contribution to journalArticlepeer-review

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and predisposes to an increased risk of thromboembolic events. Patients affected by AF exhibit an increased risk of stroke compared with those in sinus rhythm, with the most common location of thrombi in the left atrial appendage. Until 2009, warfarin and other vitamin K antagonists were the only class of oral anticoagulants available. More recently, dabigatran, rivaroxaban, apixaban, and edoxaban have been approved by regulatory authorities for prevention of stroke in patients with non-valvular AF. Few data are available about the efficacy of novel oral anticoagulants for the treatment of left atrial and left atrial appendage thrombosis. Aim of this review is to summarize available evidence regarding the effectiveness of novel oral anticoagulants on left atrial appendage thrombosis.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalJournal of Thrombosis and Thrombolysis
DOIs
Publication statusAccepted/In press - Sep 10 2016

Keywords

  • Atrial fibrillation
  • Left atrial appendage thrombus
  • Novel oral anticoagulants
  • Stroke

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal'. Together they form a unique fingerprint.

Cite this